Autres langues Tempus AI, Inc.

Actions

TEM

US88023B1035

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 19:32:07 10/09/2026			Varia. 5j.	Varia. 1 janv.
58,94 ^USD	-3,81%		-8,48%	+0,22%

09/09	Tempus AI obtient jusqu'à 9,5 millions de dollars de financement d'une agence américaine pour un agent en cardiologie	MT
09/09	Tempus AI, Inc. : UBS neutre sur le dossier	ZM

Autres langues

09/09	Tempus AI Secures Up To $9.5 Million in US Agency Funding for Cardiology Agent
09/09	Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in Cardiology
09/09	Q1 Report - Focused Execution Driving Growth
04/09	Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
03/09	Median Technologies Announces Formation of Strategic Review Committee and R&D Committee to Unlock Intrinsic Value and Accelerate Its eyonis Pan-Cancer Strategy
01/09	Afternoon Meeting: La renta fija empaña el inicio de septiembre
01/09	Bonds spoil September's opening
01/09	Analyst recommendations: Duolingo, Robinhood, Adobe, CrowdStrike, Salesforce…
24/08	Tempus AI Receives FDA Clearance For Tempus ECG-PH AI Product Intended To Detect Signs Of Pulmonary Hypertension From Standard ECGs
24/08	Tempus AI Gets FDA Clearance for AI-Enabled Pulmonary Hypertension Detector
24/08	Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs
21/08	Tempus AI Insider Sold Shares Worth $2,038,723, According to a Recent SEC Filing
21/08	Tempus AI Insider Sold Shares Worth $6,577,840, According to a Recent SEC Filing
21/08	Tempus AI Insider Sold Shares Worth $2,696,444, According to a Recent SEC Filing
21/08	Tempus AI Insider Sold Shares Worth $1,542,674, According to a Recent SEC Filing
11/08	Tempus AI Insider Sold Shares Worth $1,000,800, According to a Recent SEC Filing
06/08	CellCarta Inc. And Tempus AI, Inc. Enter Strategic Collaboration For CDx Commercialization Lab Network
06/08	Tempus AI Insider Sold Shares Worth $1,100,076, According to a Recent SEC Filing
04/08	Tempus Ai, Inc. Announces Study Results Demonstrating Prism2 Multimodal Slide-Level Pathology Foundation Model Performance
04/08	Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications
31/07	Tempus Ai Insider Sold Shares Worth $10,514,914, According to a Recent SEC Filing
30/07	Tempus AI, Inc. Revises Earnings Guidance for the Full Year 2026
30/07	Tempus AI Q2 Adjusted Loss Narrows, Revenue Rises
30/07	(TEM) Tempus AI Expects Full Year 2026 Revenue Range $1.595B - $1.605B, vs. FactSet Est of $1.59B
30/07	Tempus: Q2 Earnings Snapshot